Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 12,000 shares at $2.41 ($29K) on 2014-11-04, disclosed to the SEC on 2014-11-06.
Scheduled sale ($29k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.37 | 900 | $2K | 7.4% |
| 2 | $2.38 | 2,700 | $6K | 22.4% |
| 3 | $2.39 | 2,400 | $6K | 20.0% |
| 4 | $2.39 | 2,500 | $6K | 20.8% |
| 5 | $2.40 | 1,000 | $2K | 8.4% |
| 6 | $2.40 | 800 |
| $2K |
| 6.7% |
| 7 | $2.41 | 1,700 | $4K | 14.3% |
| Total | $2.39 avg | 12,000 | $29K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |